Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
LEGN Stock Chart & Stats
$21.65
-$0.50(-1.49%)
At close: 4:00 PM EST
$21.65
-$0.50(-1.49%)
Day’s Range― - ―
52-Week Range$21.51 - $45.30
Previous CloseN/A
Volume249.07K
Average Volume (3M)2.21M
Market Cap
$4.00B
Enterprise Value$5.44B
Total Cash (Recent Filing)$992.59M
Total Debt (Recent Filing)$410.24M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Mar 18, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding184,570,710
10 Day Avg. Volume3,022,576
30 Day Avg. Volume2,207,494
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)2.86
Price to Sales (P/S)4.74
P/FCF Ratio-18.81
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue5.98
Enterprise Value/Gross Profit9.88
Enterprise Value/Ebitda-29.67
Forecast
1Y Price Target
$68.20Price Target Upside215.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$1.03B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLegend management remains reasonably confident they can achieve FY25 consensus of $1.9B.
Manufacturing And SupplyLegend confirmed that manufacturing capacity now meets market demand, eliminating prior patient wait times.
Regulatory AdvantageThe convergence of the regulatory moat, unmatched five-year functional cure data, and a commercial lead of ~10,000 patients treated creates a fortress around the franchise that is virtually impenetrable by late entrants.
Bears Say
Competitive HeadwindsBispecific growth validates demand but might temper 2L CAR-T use, potentially creating competitive headwinds for CARVYKTI.
Investor SentimentStock reaction remains muted despite CARVYKTI consistently exceeding Street expectations, indicating investor fatigue with incremental beats.
Safety ConcernsCarvykti label updated to include new safety warnings, including immune effector cell-associated enterocolitis as a black-boxed warning.
Legend Biotech News
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $21.51 and its highest was $45.30 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $4.00B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Mar 18, 2026 which is in 89 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Nov 12, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.073 by -$0.037.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is -0.02.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 184,570,710 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.073. Following the earnings report the stock price went down -2.654%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Legend Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.20 (215.01% Upside)
$68.20 (215.01% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 100%
Sector Average 68%
Sector Average 68%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.7%
Last 30 Days ▲ 15.8%
Last 30 Days ▲ 15.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.41%
12-Months-Change
Fundamentals
Return on Equity
-22.60%
Trailing 12-Months
Asset Growth
-1.32%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech (LEGN) is a clinical-stage biotechnology company focused on the development of innovative cell therapies for the treatment of cancer and other serious diseases. The company operates primarily in the biopharmaceutical sector, leveraging its proprietary technology platform to create chimeric antigen receptor (CAR) T-cell therapies. Its core product is the investigational CAR T-cell therapy, which aims to provide treatment options for patients with hematological malignancies and solid tumors.
LEGN Company Deck
LEGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a largely positive outlook driven by significant sales growth of CARVYKTI, successful international expansion, and advancements in clinical trials and manufacturing capacity. However, challenges like managing neurotoxicity and achieving profitability remain.View all LEGN earnings summariesLEGN Stock 12 Month Forecast
Average Price Target
$68.20
▲(215.01% Upside)
Technical Analysis
Cytokinetics
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Avidity Biosciences
―
Abivax SA Sponsored ADR
―
Ownership Overview
―
Insiders
15.92% Mutual Funds
17.47% Other Institutional Investors
63.95% Public Companies and Individual Investors